Rifaximin (Targaxan®)

Assessment Status Rapid Review Complete
Drug Rifaximin
Brand Targaxan®
Indication Is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age. 
Assessment Process
Rapid review commissioned 09/07/2013
Rapid review completed 06/08/2013
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended